Heron Therapeutics, Inc. (HRTX)

NCM – Цена в реальном времени. Валюта: USD

0.92

-0.04 (-4.58%)

Рынок открыт: May 13, 2026, 9:48 AM EDT

11.05.2026

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

11.05.2026

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.

11.05.2026

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

11.05.2026

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

11.05.2026

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.

04.05.2026

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

27.04.2026

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.

Видео

No Data

There is no data to display

Пресс-релизы

11.05.2026

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

26.02.2026

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.

09.01.2026

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron.

04.12.2025

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

CARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary and Full Report as published in Anesthesia and Analgesia (collectively, the “PONV Guidelines”).

Heron Therapeutics, Inc. (HRTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Видео

No Data

Пресс-релизы

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Видео

No Data

Пресс-релизы

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Search stocks

Heron Therapeutics, Inc. (HRTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Видео

No Data

Пресс-релизы

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Видео

No Data

Пресс-релизы

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)